Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glulisine plus insulin glargine versus conventional twice-daily insulin in poorly controlled type 2 diabetes
2004-001287-49Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human insulin and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in glycated hemoglobin A1c from baseline to endpoint. Started Sep 2004; status: completed.
02
Drugs
human insulininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-001287-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001287-49.